<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628871</url>
  </required_header>
  <id_info>
    <org_study_id>ST-IVPRP-LT01</org_study_id>
    <nct_id>NCT04628871</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX</brief_title>
  <acronym>LTFU</acronym>
  <official_title>Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial&#xD;
      and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled&#xD;
      subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913,&#xD;
      or SB-FIX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with&#xD;
      SB-318 in the clinical study SB-318-1502, SB-913 in the clinical study SB-913-1602, and&#xD;
      SB-FIX in clinical study SB-FIX-1501. All subjects dosed in the studies and completed at&#xD;
      least 52 weeks post-infusion follow-up in their primary protocol will be offered to&#xD;
      participate. Subjects who enroll will be monitored for a total of up to 10 years following&#xD;
      exposure to the respective investigational products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety</measure>
    <time_frame>10 years</time_frame>
    <description>Long-term safety of SB-318, SB-913, and SB-FIX by assessment of any newly-diagnosed or worsening of existing medical conditions.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Hemophilia B</condition>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Subjects who received SB-318</arm_group_label>
    <description>Subjects who received SB-318 in clinical study SB-318-1502</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who received SB-913</arm_group_label>
    <description>Subjects who received SB-913 in clinical study SB-913-1602.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who received SB-FIX</arm_group_label>
    <description>Subjects who received SB-FIX in clinical study SB-FIX</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-318</intervention_name>
    <description>No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.</description>
    <arm_group_label>Subjects who received SB-318</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-913</intervention_name>
    <description>No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.</description>
    <arm_group_label>Subjects who received SB-913</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-FIX</intervention_name>
    <description>No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.</description>
    <arm_group_label>Subjects who received SB-FIX</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who have received SB-318 in Study Protocol SB-318-1502, SB-913 in Study&#xD;
        Protocol SB-913-1602 or SB-FIX in Study Protocol SB-FIX-1501 and who have consented to&#xD;
        participate in this Long Term Follow-up study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who received SB-318 under Study Protocol SB-318-1502, SB-913 under Study&#xD;
             Protocol SB-913-1602, or SB-FIX under Study Protocol SB-FIX-1501&#xD;
&#xD;
          2. Subjects who have provided consent to participate in the LTFU study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to comply with study visit schedule or study visit procedures.&#xD;
&#xD;
          2. Any other reason that, in the opinion of the Investigator or Medical Monitor, would&#xD;
             render the subject unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Grossman School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>Hurler-Scheie Syndrome</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Hunter Syndrome</keyword>
  <keyword>Gene Editing</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Zinc Finger</keyword>
  <keyword>SB-318</keyword>
  <keyword>SB-913</keyword>
  <keyword>SB-FIX</keyword>
  <keyword>Rare</keyword>
  <keyword>Genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>ZFN</keyword>
  <keyword>Long Term</keyword>
  <keyword>Hemophilia B</keyword>
  <keyword>MPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

